Unlock instant, AI-driven research and patent intelligence for your innovation.

Adeno-associated virus variant capsids and methods of use thereof

A mutation, virus technology, applied in chemical instruments and methods, botanical equipment and methods, biochemical equipment and methods, etc.

Pending Publication Date: 2020-10-27
4D MOLECULAR THERAPEUTICS INC
View PDF79 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although AAV-based clinical gene therapy has been increasingly successful, there are still shortcomings in the nature of viral vectors, including, for example, targeting desired myocytes with high efficiency.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adeno-associated virus variant capsids and methods of use thereof
  • Adeno-associated virus variant capsids and methods of use thereof
  • Adeno-associated virus variant capsids and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0092] Adeno-associated viruses (AAV) are a family of parvoviruses with a 4.7 kb single-stranded DNA genome contained within a non-enveloped capsid. The viral genome of naturally occurring AAV has 2 inverted terminal repeats (ITRs) - which function as the viral source of replication and packaging signals - flanked by 2 major open reading frames (ORFs): rep (encoded in the viral replication , transcription regulation, site-specific integration and virion assembly) and cap. The cap ORF encodes three structural proteins that assemble to form the 60-mer viral capsid. Many naturally occurring AAV variants and serotypes have been isolated, and none have been associated with human disease.

[0093]Recombinant versions of AAV can be used as gene delivery vectors, where a relevant marker or therapeutic gene is inserted between the ITRs replacing rep and cap. These vectors have been shown to transduce both dividing and non-dividing cells in vitro and in vivo, and can produce stable tr...

example

[0291] The following examples are presented so as to fully disclose and describe to those of ordinary skill in the art how to make and use the invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent that the experiments below are all performed or single experiment. Efforts have been made to ensure accuracy with respect to quantities used (eg amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

[0292] General methods of molecular and cellular biochemistry can be found in such standard textbooks as Molecular Cloning: A Laboratory Manual, 3rd Edition, (Sambrook et al., Harbor Laboratory Press 2001); Short Protocols in Molecular Biology, 4th Edition, (Ausubel et al., John Wi...

example 1

[0294] Intravenous injection and tissue collection. For each round of selection, a single male cynomolgus monkey (cynomolgus monkey) aged 3-10 years and weighing at least 3 kg was administered intravenously via the great saphenous vein. Animals were anesthetized and dosed with 1-5 mL of the pool (in the first round, the pool was used by figure 1 Variant composition generated by all mutagenesis techniques described in A; in each subsequent round, variants were isolated from previous rounds), in some cases pre-incubated with human IVIG for 30 min at 37°C.

[0295] Euthanasia was performed by trained veterinary personnel using 100 mg / kg sodium pentobarbital intravenously on day 14±3 or 21±3, depending on choice. Cardiac and / or skeletal muscle tissue from the quadriceps is removed and DNA is isolated from the tissue. In some cases, myocardial tissue is divided into several regions: atrium, ventricular septum, left papillary muscle, right papillary muscle, left ventricle, and ri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of muscle cells as compared to the infectivity of the muscle cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions,and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more muscle cells for the treatment of muscle disorders and diseases.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 560,901, filed September 20, 2017, the entire disclosure of which application is incorporated herein by reference. technical field [0003] The invention disclosed herein relates generally to the field of adeno-associated virus (AAV) virions comprising variant capsid proteins and the use of directed evolution techniques to generate such variant capsids. Background technique [0004] Muscle is associated with several serious genetic conditions. Muscle is the target tissue in many gene therapies for muscular dystrophy and can also be used as a biofactory to produce secreted factors to treat systemic disease. Delivery of therapeutic genes to human muscle tissue is arguably the most pressing unmet need for the treatment of muscle-related diseases. [0005] One approach to achieving muscle-targeted gene delivery is gene-based adeno-associat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00C12N15/861
CPCC07K14/005C12N15/86C12N2750/14121C12N2750/14122C12N2750/14143C12N2750/14145A61K48/00A61P21/00C07K14/05C12N7/00C12N15/861A61K9/0019C12N15/8645A61K38/47C12N2750/14171C12Y302/01022A61K38/1719A61K38/44C12N9/1051C12N2750/14133C12Y116/03001C12Y204/01001C12Y302/0102
Inventor D.H.柯恩M.科特曼D.谢弗
Owner 4D MOLECULAR THERAPEUTICS INC